Revisiting monoamine oxidase inhibitors.
Publication
, Journal Article
Krishnan, KR
Published in: J Clin Psychiatry
2007
Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.
Duke Scholars
Published In
J Clin Psychiatry
EISSN
1555-2101
Publication Date
2007
Volume
68 Suppl 8
Start / End Page
35 / 41
Location
United States
Related Subject Headings
- Psychiatry
- Monoamine Oxidase Inhibitors
- Humans
- Depressive Disorder
- Administration, Cutaneous
- 3202 Clinical sciences
- 17 Psychology and Cognitive Sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Krishnan, K. R. (2007). Revisiting monoamine oxidase inhibitors. J Clin Psychiatry, 68 Suppl 8, 35–41.
Krishnan, K Ranga. “Revisiting monoamine oxidase inhibitors.” J Clin Psychiatry 68 Suppl 8 (2007): 35–41.
Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68 Suppl 8:35–41.
Krishnan, K. Ranga. “Revisiting monoamine oxidase inhibitors.” J Clin Psychiatry, vol. 68 Suppl 8, 2007, pp. 35–41.
Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68 Suppl 8:35–41.
Published In
J Clin Psychiatry
EISSN
1555-2101
Publication Date
2007
Volume
68 Suppl 8
Start / End Page
35 / 41
Location
United States
Related Subject Headings
- Psychiatry
- Monoamine Oxidase Inhibitors
- Humans
- Depressive Disorder
- Administration, Cutaneous
- 3202 Clinical sciences
- 17 Psychology and Cognitive Sciences
- 11 Medical and Health Sciences